Form 4: Oramed Pharmaceuticals Director Benjamin Shapiro Boosts Stake with Significant RSU Grants

Oramed Pharmaceuticals Director and 10% owner Benjamin Shapiro has increased his beneficial ownership in the company through the acquisition of 34,650 Restricted Stock Units (RSUs) on June 5, 2025.

Summary

• Benjamin Shapiro, a Director and 10% owner of Oramed Pharmaceuticals Inc. (ORMP), reported changes in his beneficial ownership via a Form 4 filing.
• On June 5, 2025, Mr. Shapiro acquired 30,000 Restricted Stock Units (RSUs) which are scheduled to vest in three equal annual installments of 10,000 shares on January 1, 2026, January 1, 2027, and January 1, 2028.
• Additionally, on the same date, he acquired 4,650 RSUs that will vest in equal installments on grant, July 1, 2025, October 1, 2025, and January 1, 2026.
• These RSUs convert into Oramed's Common Stock on a one-for-one basis.
• Following these transactions, Mr. Shapiro's direct beneficial ownership stands at 89,720 shares of Common Stock.
• He also indirectly beneficially owns 1,900,000 shares of Common Stock through a trust, where he serves as both a trustee and a beneficiary.

Sentiment

Score: 7

Explanation: The acquisition of additional shares by a director, particularly through RSU grants with multi-year vesting, generally indicates confidence in the company's future prospects and aligns management incentives with long-term shareholder value, which is a positive signal for investors.

Positives

• Director Benjamin Shapiro increased his direct beneficial ownership by 34,650 shares through RSU grants, signaling continued commitment and confidence in the company's future.
• The multi-year vesting schedule for the RSUs (extending to January 2028 for a significant portion) indicates a long-term alignment of the director's interests with shareholder value.

Future Outlook

The document primarily details insider transactions and RSU vesting schedules, rather than providing forward-looking statements or guidance on the company's financial performance or strategic outlook.

Industry Context

This Form 4 filing is a standard regulatory disclosure for insider transactions, indicating a change in beneficial ownership by a director. Such filings are common across all industries for publicly traded companies and provide transparency into executive and significant shareholder activity.

Stakeholder Impact

• Shareholders: The increase in director ownership through RSU grants aligns the interests of Benjamin Shapiro with those of public shareholders, potentially signaling confidence in the company's long-term performance and commitment to value creation.

Next Steps

• Vesting of 4,650 RSUs in installments on grant, July 1, 2025, October 1, 2025, and January 1, 2026.
• Vesting of 30,000 RSUs in equal portions on January 1, 2026, January 1, 2027, and January 1, 2028.

Key Dates

Recommendation

Keywords

Oramed Pharmaceuticals, ORMP, Benjamin Shapiro, SEC Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, RSU, Director, 10% Owner, Stock Acquisition